Welcome to our dedicated page for Microbot Med SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for hard numbers on Microbot Medical’s cash runway or the latest patent additions behind its LIBERTY micro-robotic platform? Investors typically start with the 10-K annual report, but wading through hundreds of pages of R&D tables can be time–consuming. Our SEC filings hub anticipates that journey and answers the common search, “Microbot Medical SEC filings explained simply,” with clear context for every document.
The moment a Microbot Medical quarterly earnings report 10-Q filing or an 8-K material event posts to EDGAR, Stock Titan delivers real-time access plus AI-powered summaries that translate clinical trial jargon into plain language. Need to monitor executive moves? Track every Microbot Medical insider trading Form 4 transactions notice alongside Microbot Medical Form 4 insider transactions real-time alerts so you never miss a buy or sell.
- See R&D expense trends with “Microbot Medical earnings report filing analysis.”
- Review patent milestones and regulatory disclosures through “Microbot Medical 8-K material events explained.”
- Compare leadership pay packages inside the “Microbot Medical proxy statement executive compensation.”
Each filing page pairs the original PDF with an easy-to-scan AI digest—ideal for understanding Microbot Medical SEC documents with AI when minutes matter. Whether you’re deciphering a Microbot Medical annual report 10-K simplified section on intellectual property or spotting patterns in a Microbot Medical executive stock transactions Form 4, our platform connects the dots, surfaces key figures, and updates automatically. Stop searching multiple sources; everything you need is organized in one place, refreshed the instant Microbot Medical submits a new disclosure.
Cellectar Biosciences (Nasdaq: CLRB) filed Amendment No. 1 to its Form S-1 on 30 June 2025, seeking to register a follow-on public offering of up to 755,667 Class A Units or, at investors’ election, an equal number of Class B Units. Each Class A Unit contains one share of common stock and one five-year common warrant; each Class B Unit substitutes the share with a pre-funded warrant priced at $0.00001 to mitigate ownership-limit issues (4.99% or 9.99% caps).
The filing covers up to 1,556,674 shares issuable upon exercise of pre-funded, common and representative warrants, plus an underwriters’ 45-day over-allotment option for up to 113,350 additional shares and/or warrants. Representative warrants equal to 6% of units sold will also be issued. The assumed public offering price is $7.94, the last closing price on 25 June 2025; final pricing will be set through negotiation with lead underwriter Ladenburg Thalmann.
On 24 June 2025 the company completed a 1-for-30 reverse stock split, leaving authorized share count and par value unchanged. Following the split, Cellectar remains a non-accelerated filer and smaller reporting company. The S-1 reiterates that investing in the securities involves a “high degree of risk,” directing readers to a dedicated Risk Factors section starting on page 17. Proceeds, net of underwriting fees and expenses, are not quantified here and will depend on final pricing and warrant exercise, while the company reserves the right to delay effectiveness until it files a further amendment.
FAQ
What is the current stock price of Microbot Med (MBOT)?
What is the market cap of Microbot Med (MBOT)?
What is Microbot Medical Inc's primary focus?
How does the company aim to improve surgical outcomes?
What distinguishes Microbot Medical's technology from traditional surgical tools?
What role does intellectual property play in Microbot Medical's strategy?
How does Microbot Medical contribute to the field of minimally invasive surgery?
How does Microbot Medical differentiate itself from its competitors?
